The presence of BLM can enhance the degradation of c-Myc (Chandra et al., 2013) in vitro and it was hypothesized that there may exist a reciprocal relationship in the expression levels of these two proteins in different stages of neoplastic transformation, and tumor sub-types.
In Colorectal cancer we plan to define the clinical subtypes by MSI status in the commercially available TMA slides by screening for the four MMR (Mis-Match Repair) proteins namely MLH1, MSH2, PMS2 and MSH6 by Immunohistochemistry. We intend to explore the reciprocal relationship of BLM and cMyc and its clinical relevance in our established breast cancer case series collected from a regional cancer center in Bangalore and the commercially available Colorectal cancer TMA.